SELLAS Life Sciences (SLS) Total Current Liabilities (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Total Current Liabilities of $6.5 million for Q1 2026, down 6.27% year-over-year from $6.9 million in Q1 2025, and down 7.99% quarter-over-quarter from $7.0 million in Q4 2025.
SELLAS Life Sciences (SLS) Total Current Liabilities (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Total Current Liabilities for 17 consecutive years, with $6.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 6.27% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $6.5 million (down 6.27% YoY), while the FY2025 annual figure was $7.0 million, down 26.21% from the prior year.
- Total Current Liabilities declined to $6.5 million in Q1 2026 per SLS's latest filing, from $7.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $15.5 million in Q4 2022 and bottomed at $5.9 million in Q3 2025.
- Historically, Total Current Liabilities has averaged $10.8 million across 5 years, with a median of $11.7 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 211.42% — and 2025, when it plunged 52.29%.
- SELLAS Life Sciences' Total Current Liabilities stood at $15.5 million in 2022, then retreated by 11.47% to $13.7 million in 2023, then plunged by 30.76% to $9.5 million in 2024, then fell by 26.21% to $7.0 million in 2025, then decreased by 7.99% to $6.5 million in 2026.
- Business Quant data shows SLS's Total Current Liabilities at $6.5 million in Q1 2026, $7.0 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 7.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.57 Mn |
| Mar 31, 2026 | 6.46 Mn |
| Dec 31, 2025 | 7.02 Mn |
| Sep 30, 2025 | 5.93 Mn |
| Jun 30, 2025 | 6.00 Mn |
| Mar 31, 2025 | 6.89 Mn |
| Dec 31, 2024 | 9.51 Mn |
| Sep 30, 2024 | 10.61 Mn |
| Jun 30, 2024 | 12.05 Mn |
| Mar 31, 2024 | 14.44 Mn |
| Dec 31, 2023 | 13.74 Mn |
| Sep 30, 2023 | 11.74 Mn |
| Jun 30, 2023 | 13.42 Mn |
| Mar 31, 2023 | 15.51 Mn |
| Dec 31, 2022 | 15.52 Mn |
| Sep 30, 2022 | 12.55 Mn |
| Jun 30, 2022 | 12.19 Mn |
| Mar 31, 2022 | 10.68 Mn |
| Dec 31, 2021 | 4.98 Mn |
| Sep 30, 2021 | 5.32 Mn |